Detalles de la búsqueda
1.
Rationale and study protocol of ACQUIRE, a prospective, observational study measuring quality of life, treatment preference and treatment satisfaction of autosomal dominant polycystic kidney disease (ADPKD) patients in Europe.
BMC Nephrol
; 21(1): 298, 2020 07 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32709218
2.
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
BMC Nephrol
; 20(1): 136, 2019 04 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31014270
3.
A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model.
BMC Nephrol
; 19(1): 37, 2018 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-29439650
4.
A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans.
Clin Endocrinol (Oxf)
; 86(6): 761-771, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28214374
5.
Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
BMC Endocr Disord
; 16(1): 22, 2016 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-27184496
6.
A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease.
BMC Nephrol
; 16: 140, 2015 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26275819
7.
Caregiver burden in cystic fibrosis: a systematic literature review.
Ther Adv Respir Dis
; 16: 17534666221086416, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35323061
8.
Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia.
Cancer Treat Rev
; 69: 224-232, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30098484
Resultados
1 -
8
de 8
1
Próxima >
>>